The Pagoclone study is wrapping up - with results the drug company finds less than compelling, according to my contact at the research center that's been administering my participation in the study.
Many subjects, he tells me, have reported similar effects as those I have experienced: reduced tension in the larynx and/or articulators and at least some improvement in fluency. These positive effects are not powerful or compelling enough for the drug company to push for FDA approval at this time. My contact thinks they will engage in another study at a higher dose of the drug, with the hope that it will yield more promising results.
I am on my last three bottles of Pagoclone and will return to the research center in November for a final visit.